Tag Archives: catalysts

Development stage biotechnology company Nemus Bioscience Inc (OTCMKTS:NMUS) just announced that it raised $20 million by way of series E preferred stock financing, and the company has taken a bit of a hit on the back of the news. From its May...

We keep coming back to Cellceutix Corp (OTCMKTS:CTIX), and each time we do, we proclaim that the company is undervalued at its current price. Despite our repeated efforts at trying to get this across, however, markets are still to come round...

Bellerophon Therapeutics Inc (NASDAQ:BLPH) put out some data at the end of last week relates to its lead development asset, INOpulse. Markets have sold off on the company since release, and Bellerophon shares currently trade at an around 20%...

When we highlighted Benitec Biopharma Ltd (ADR) (NASDAQ:BNTC) as being one to watch earlier this year, the company was running up on some news related to its ocular therapy pipeline. We noted that there were plenty of opportunities for Benitec...

Delcath Systems, Inc. (NASDAQ:DCTH) has had a pretty tough start to 2017, with the company down a little shy of 90% on its January open. It’s one that we’ve taken a look at a few times in the past, and highlighted as being a company...

Bellerophon Therapeutics Inc (NASDAQ:BLPH) is all over the place at the moment. The company traded for around $.50 a share back in January, and ran up to highs of just shy of $2 a share at the beginning of this month. At the end of last week,...

Bellerophon Therapeutics Inc (NASDAQ:BLPH) is a real runner this week, with the company currently trading around $1.50 a share – a close to 40% gain on its weekly open and a more than 65% premium on last week’s mid week pricing. At first...

At the beginning of February, we published this article on Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX), noting the upside momentum seen during the period running up to our coverage, and attempting to ascertain whether this action was a one-off...

Matinas BioPharma Holdings Inc (OTCMKTS:MTNB) put out a business outlook at the end of January, and alongside the outlook, gave markets a number of milestones to keep an eye on across the coming twelve months. This is one we’ve looked at...

Towards the end of January, we highlighted Cellectar Biosciences Inc (NASDAQ:CLRB) as being a company to keep an eye on across the next six to eight weeks. The company had a number of potential catalysts that – at then-time of writing –...

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter